Physician profile
Mark E Willcox
NPI 1336395599
$14,344.92
in general payments reported to CMS, 2019-2025
14 companies · $1,658 in 2025
The $1,658 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $128 · 2021: $299 · 2022: $5,925 · 2023: $5,619 · 2024: $515 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,450 · Food and Beverage: $2,459 · Travel and Lodging: $1,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,450.00 |
| Food and Beverage | $2,458.53 |
| Travel and Lodging | $1,883.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $10,056.00 | 2022-2025 | Affera Mapping System, Na |
| Abbott Laboratories | $2,376.67 | 2021-2025 | Aveir, Ensite, Ensite Precision |
| Boston Scientific Corporation | $733.02 | 2020-2025 | Watchman Flx, Watchman Access System, General - Therapies |
| Biosense Webster, INC. | $416.36 | 2019-2025 | Carto 3, Nuvision Ice Catheter |
| Impulse Dynamics (USA) INC. | $282.15 | 2022-2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $227.85 | 2019-2025 | Eliquis, Camzyos |
| Alnylam Pharmaceuticals INC. | $65.20 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $49.19 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $48.66 | 2022-2023 | |
| Amgen INC. | $40.40 | 2023-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $18.76 | 2022 | |
| Edwards Lifesciences Corporation | $16.69 | 2022 | |
| Pfizer INC. | $13.97 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Willcox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.